Bradley Duffy

Array ( [id] => 12118849 [patent_doc_number] => 20180002435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS' [patent_app_type] => utility [patent_app_number] => 15/546630 [patent_app_country] => US [patent_app_date] => 2016-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 28445 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15546630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13222865 [patent_doc_number] => 10125197 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-13 [patent_title] => Cytotoxic immunoglobulin [patent_app_type] => utility [patent_app_number] => 15/004692 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 49 [patent_no_of_words] => 27785 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15004692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461751 [patent_doc_number] => 20180282418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => INHIBITORS OF THE INTERACTION BETWEEN CLEC14A AND MULTIMERIN-2 FOR INHIBITION OF ANGIOGENESIS [patent_app_type] => utility [patent_app_number] => 15/544323 [patent_app_country] => US [patent_app_date] => 2016-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15544323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150115 [patent_doc_number] => 20180021378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS' [patent_app_type] => utility [patent_app_number] => 15/541006 [patent_app_country] => US [patent_app_date] => 2015-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 62470 [patent_no_of_claims] => 214 [patent_no_of_ind_claims] => 82 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15541006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992469 [patent_doc_number] => 20170296623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN' [patent_app_type] => utility [patent_app_number] => 15/532430 [patent_app_country] => US [patent_app_date] => 2015-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 51660 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15532430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12565962 [patent_doc_number] => 10017561 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Neutralizing molecules to influenza viruses [patent_app_type] => utility [patent_app_number] => 14/970244 [patent_app_country] => US [patent_app_date] => 2015-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 13 [patent_no_of_words] => 25149 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14970244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10755999 [patent_doc_number] => 20160102152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'IMMUNOGLOBULIN VARIABLE REGION CASSETTE EXCHANGE' [patent_app_type] => utility [patent_app_number] => 14/968709 [patent_app_country] => US [patent_app_date] => 2015-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19084 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14968709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11046264 [patent_doc_number] => 20160243223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'METHODS FOR TREATING CANCERS COMPRISING K-RAS MUTATIONS' [patent_app_type] => utility [patent_app_number] => 14/962127 [patent_app_country] => US [patent_app_date] => 2015-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24334 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14962127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17451902 [patent_doc_number] => 11266739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Methods and compositions for adoptive cell therapy [patent_app_type] => utility [patent_app_number] => 14/958919 [patent_app_country] => US [patent_app_date] => 2015-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 51555 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14958919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10997774 [patent_doc_number] => 20160194720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'DIFFERENTIAL GENE EXPRESSION IN PHYSIOLOGICAL AND PATHOLOGICAL ANGIOGENESIS' [patent_app_type] => utility [patent_app_number] => 14/954509 [patent_app_country] => US [patent_app_date] => 2015-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 31269 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14954509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10813769 [patent_doc_number] => 20160159930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-09 [patent_title] => 'BISPECIFIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 14/934956 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 27768 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14934956 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13457923 [patent_doc_number] => 20180280504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/518214 [patent_app_country] => US [patent_app_date] => 2015-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15518214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001884 [patent_doc_number] => 20170306038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/517872 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 86488 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12001881 [patent_doc_number] => 20170306037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-26 [patent_title] => 'COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY' [patent_app_type] => utility [patent_app_number] => 15/517867 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 46846 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11060776 [patent_doc_number] => 20160257738 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'ANTI-VEGF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/876021 [patent_app_country] => US [patent_app_date] => 2015-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 30375 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14876021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371989 [patent_doc_number] => 20180237535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => PD-L1 ANTIBODIES BINDING CANINE PD-L1 [patent_app_type] => utility [patent_app_number] => 15/514920 [patent_app_country] => US [patent_app_date] => 2015-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15514920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10800674 [patent_doc_number] => 20160146830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-26 [patent_title] => 'PROTEOMIC IDENTIFICATION OF ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/865302 [patent_app_country] => US [patent_app_date] => 2015-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 28619 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14865302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11993975 [patent_doc_number] => 20170298131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/511792 [patent_app_country] => US [patent_app_date] => 2015-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 22665 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491582 [patent_doc_number] => 20150376603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'METHOD FOR ENGINEERING IMMUNOGLOBULINS' [patent_app_type] => utility [patent_app_number] => 14/853919 [patent_app_country] => US [patent_app_date] => 2015-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 29762 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14853919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977469 [patent_doc_number] => 20170281624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'COMBINATION THERAPIES OF ALK INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/509649 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 35233 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509649 [rel_patent_id] =>[rel_patent_doc_number] =>)